MGNX News Alert Macrogenics Inc (MGNX) 33.00 12/25/2014 15:1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Macrogenics Inc (MGNX) 33.00 $MGNX

MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31), MDCO: 27.06 (+0.21), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)

MacroGenics investors take some money off the table
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:12AM CST

MGNX: 33.00 (+0.34)

Equities Lead Investor Sentiments: Coverage Initiated on AMETEK, FedEx, MacroGenics, Walgreens and Apple
PR Newswire - Tue Dec 23, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AMETEK (NYSE: AME), FedEx (NYSE: FDX), MacroGenics (NASDAQ: MGNX), Walgreens (NYSE: WAG), and Apple (NASDAQ: AAPL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
MGNX: 33.00 (+0.34), FDX: 176.42 (-0.52), AME: 53.98 (+0.19), AAPL: 112.01 (-0.53), WAG: 76.67 (+0.16)

MacroGenics, J&J make deal
at Investor's Business Daily - Mon Dec 22, 5:30PM CST
Biotech MacroGenics (MGNX) inked a licensing deal worth as much as $700 mil with Janssen Biotech, a Johnson & Johnson (JNJ) unit, which agreed to pay $50 mil upfront for rights to MGD011, an antibody that targets 2 biomarkers associated with...
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)

MacroGenics Partners With J&J; Stock Jumps
at Investor's Business Daily - Mon Dec 22, 11:33AM CST
Biotech MacroGenics (MGNX) cut a licensing deal worth as much as $700 million with Johnson & Johnson's drug-development arm Monday, sending its stock up 11% to a 10-month high above 38 on the stock market today. Johnson & Johnson's (JNJ) unit Janssen...
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)

MacroGenics teams up with Janssen in blood cancer
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:08AM CST

MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)

MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
GlobeNewswire - Mon Dec 22, 5:00AM CST
-- MacroGenics licenses MGD011 (CD19 x CD3 DART(R)) to Janssen
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31)

Is Boston Scientific (BSX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:50PM CST
On Dec 16, 2014, Zacks Investment Research upgraded Boston Scientific Corporation (BSX) to a Zacks Rank #2 (Buy).
MGNX: 33.00 (+0.34), BSX: 13.13 (+0.07), ABAX: 58.48 (+0.22), HSP: 62.60 (-0.07)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

MacroGenics (MGNX) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:27AM CST
MacroGenics (MGNX) Stock: Moving Average Crossover Alert
MGNX: 33.00 (+0.34)

B7-H3 And PD-1: Are All Checkpoint Inhibitors Created Equal?
Mark Kroenke - Seeking Alpha - Mon Dec 15, 7:43AM CST
Checkpoint inhibitors are a big deal. What started with ipilimumab has now grown into a class of drugs which are being pursued vigorously by nearly every major pharmaceutical company in the world. In this crowded space, it's worth noting that B7-H3...
MGNX: 33.00 (+0.34)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

MacroGenics Announces Presentation of Pre-clinical Data on new DART(r) Candidate MGD011 at 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Sat Dec 06, 7:30PM CST
December 6, 2014 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of pre-clinical data for MGD011, a humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART(R)) protein, at the 56 Annual Meeting of the American Society of Hematology (ASH), taking place in San Francisco, CA. These data demonstrate potent T-cell mediated anti-tumor activity in preclinical models.
MGNX: 33.00 (+0.34)

MacroGenics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Wed Dec 03, 6:17AM CST
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Oppenheimer 25 Annual Healthcare Conference in New York. The presentation will take place on Wednesday, December 10, 2014, at 3:20 p.m. Eastern Time.
MGNX: 33.00 (+0.34)

Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 33.00 (+0.34), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), CTIC: 2.36 (+0.05), GSK: 42.85 (+0.11), VSTM: 8.30 (+0.19), SNTA: 2.63 (+0.02), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), AMBI: 15.60 (+0.26), CELGZ: 3.34 (-0.01), KPTI: 37.78 (+1.28), NVS: 93.91 (+0.66)

Macrogenics (MGNX) Is Strong On High Volume Today
at The Street - Mon Nov 24, 9:04AM CST
Trade-Ideas LLC identified Macrogenics (MGNX) as a strong on high relative volume candidate
MGNX: 33.00 (+0.34)

Will MacroGenics (MGNX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:39AM CST
Will MacroGenics (MGNX) Continue to Surge Higher?
MGNX: 33.00 (+0.34)

MacroGenics (MGNX) in Focus: Stock Rises 7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 7:37AM CST
MacroGenics, Inc. (MGNX) was a big mover last session, as the company saw its shares rise 7% on the day.
MGNX: 33.00 (+0.34), ICUI: 83.38 (+1.63), GWPH: 68.08 (+1.82), OSUR: 10.26 (+0.25)

MacroGenics to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 3:30PM CST
ROCKVILLE, Md., November 12, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Stifel 2014 Healthcare Conference in New York, NY. The presentation will take place on Tuesday, November 18, 2014 at 10:55 a.m. Eastern Time.
MGNX: 33.00 (+0.34)

MacroGenics Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 12:19PM CST

MGNX: 33.00 (+0.34)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 103

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 0

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 188

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 190

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 126

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 27

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 8

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 135

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Disclosure on Rathbones Group and De La Rue Plc

Updated Category News Views 144

Key Public Position Disclosure for Rathbones Group Plc Understanding the dynamics behind stock holding and market behavior is crucial for investors and stakeholders. This article sheds light on the recent public opening position disclosure made by Rathbones Group Plc regarding its interests in De La Rue Plc. According to the regulations of the Takeover Code, disclosers...

Continue Reading
ThinkAndor® Reigns as Leading AI Platform for Virtual Care

Updated Category News Views 132

ThinkAndor® Wins Top Honors in Virtual Care Solutions Andor Health's ThinkAndor® has distinguished itself yet again as the leading **AI healthcare software infrastructure**, confirmed by recent evaluations as the best virtual care platform. This notable recognition by an acclaimed market research assessment underscores the platform's unmatched capabilities in bringing...

Continue Reading
Jayud Global Logistics: Legal Actions and Investment Alerts

Updated Category News Views 165

Understanding the Securities Fraud Class Action Against Jayud The Law Offices of Howard G. Smith have announced a significant legal development involving Jayud Global Logistics Limited (NASDAQ: JYD). A class action lawsuit has been initiated on behalf of investors who purchased Jayud securities. The lawsuit covers shares bought during a specific period, and affected...

Continue Reading
Exploring the Explosive Growth of the 3D Printing Market

Updated Category News Views 101

3D Printing Market Size Analysis As of 2023, the 3D printing market was valued at USD 21.1 billion and is expected to grow to USD 118.9 billion by 2032, reflecting a compound annual growth rate (CAGR) of 21.2% during the forecast period. Current Trends Fueling Growth The 3D printing industry is experiencing remarkable expansion, driven by technological innovations and...

Continue Reading
Nexus Industrial REIT Sells Legacy Properties and Expands Operations

Updated Category News Views 111

Nexus Industrial REIT Emphasizes Focus on Industrial Real Estate Nexus Industrial REIT is creating a buzz in the market with its recent strategic initiatives. The company has officially offloaded a 50% stake in six office buildings, reinforcing its concentration on industrial properties. This transaction signifies a key moment, bolstering Nexus's standing as a prominent...

Continue Reading